Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

VOLITIONRX LTD Director's Dealing 2017

Apr 3, 2017

34395_dirs_2017-04-03_30799669-e7fc-416e-85d9-16b6283c581b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2017-03-30

Reporting Person: TERRELL JASON BRADLEY MD (Chief Medical Officer)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-03-30 Stock Option (Right to Buy) $5 A 50000 Acquired 2023-03-30 Common Stock (50000) Direct

Footnotes

F1: A total of 50,000 Options were granted on March 30, 2017 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.